MedTrace Logo

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

NCT06132880 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2023-12-06

No results posted yet for this study

Summary

The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke
  • Functional Outcomes

Interventions

DRUG

Human Urinary Kallidinogenase

Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.

OTHER

Clinical Routine Treatment

Conventional therapy of acute ischemic stroke after based on Chinese guidelines

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Beijing Tsinghua Chang Gung Hospital

    lead OTHER

Principal Investigators

  • Jian Wu · Beijing Tsinghua Changgeng Hospital

  • Zunjing Liu · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-14
Primary Completion
2026-08-28
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132880 on ClinicalTrials.gov